These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 26936398)
21. The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. Zingg D; Debbache J; Schaefer SM; Tuncer E; Frommel SC; Cheng P; Arenas-Ramirez N; Haeusel J; Zhang Y; Bonalli M; McCabe MT; Creasy CL; Levesque MP; Boyman O; Santoro R; Shakhova O; Dummer R; Sommer L Nat Commun; 2015 Jan; 6():6051. PubMed ID: 25609585 [TBL] [Abstract][Full Text] [Related]
22. Ezh2 Zimmerman SM; Nixon SJ; Chen PY; Raj L; Smith SR; Paolini RL; Lin PN; Souroullas GP Oncogene; 2022 Nov; 41(46):4983-4993. PubMed ID: 36220978 [TBL] [Abstract][Full Text] [Related]
23. Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer. Oki S; Sone K; Oda K; Hamamoto R; Ikemura M; Maeda D; Takeuchi M; Tanikawa M; Mori-Uchino M; Nagasaka K; Miyasaka A; Kashiyama T; Ikeda Y; Arimoto T; Kuramoto H; Wada-Hiraike O; Kawana K; Fukayama M; Osuga Y; Fujii T Oncotarget; 2017 Jun; 8(25):40402-40411. PubMed ID: 28418882 [TBL] [Abstract][Full Text] [Related]
24. Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors. Huang X; Yan J; Zhang M; Wang Y; Chen Y; Fu X; Wei R; Zheng XL; Liu Z; Zhang X; Yang H; Hao B; Shen YY; Su Y; Cong X; Huang M; Tan M; Ding J; Geng M Cell; 2018 Sep; 175(1):186-199.e19. PubMed ID: 30220457 [TBL] [Abstract][Full Text] [Related]
25. EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion. Yi X; Guo J; Guo J; Sun S; Yang P; Wang J; Li Y; Xie L; Cai J; Wang Z Sci Rep; 2017 Jun; 7(1):3568. PubMed ID: 28620234 [TBL] [Abstract][Full Text] [Related]
26. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions. Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011 [TBL] [Abstract][Full Text] [Related]
27. EZH2 is highly expressed in pituitary adenomas and associated with proliferation. Schult D; Hölsken A; Siegel S; Buchfelder M; Fahlbusch R; Kreitschmann-Andermahr I; Buslei R Sci Rep; 2015 Nov; 5():16965. PubMed ID: 26593398 [TBL] [Abstract][Full Text] [Related]
28. EZH2 Inhibitor GSK126 Suppresses Antitumor Immunity by Driving Production of Myeloid-Derived Suppressor Cells. Huang S; Wang Z; Zhou J; Huang J; Zhou L; Luo J; Wan YY; Long H; Zhu B Cancer Res; 2019 Apr; 79(8):2009-2020. PubMed ID: 30737232 [TBL] [Abstract][Full Text] [Related]
29. EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia. Schäfer V; Ernst J; Rinke J; Winkelmann N; Beck JF; Hochhaus A; Gruhn B; Ernst T J Cancer Res Clin Oncol; 2016 Jul; 142(7):1641-50. PubMed ID: 27169594 [TBL] [Abstract][Full Text] [Related]
31. EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas. Otsuka Y; Nishikori M; Arima H; Izumi K; Kitawaki T; Hishizawa M; Takaori-Kondo A Mol Immunol; 2020 Mar; 119():35-45. PubMed ID: 31962268 [TBL] [Abstract][Full Text] [Related]
32. In-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAFV600E in melanoma. Guo X; Xu Y; Zhao Z Mol Cancer; 2015 Mar; 14():60. PubMed ID: 25890285 [TBL] [Abstract][Full Text] [Related]
33. Integrative Copy Number Analysis of Uveal Melanoma Reveals Novel Candidate Genes Involved in Tumorigenesis Including a Tumor Suppressor Role for Anbunathan H; Verstraten R; Singh AD; Harbour JW; Bowcock AM Clin Cancer Res; 2019 Aug; 25(16):5156-5166. PubMed ID: 31227497 [TBL] [Abstract][Full Text] [Related]
34. Synergistic triad epistasis of epigenetic H3K27me modifier genes, EZH2, KDM6A, and KDM6B, in gastric cancer susceptibility. Lee SW; Park DY; Kim MY; Kang C Gastric Cancer; 2019 May; 22(3):640-644. PubMed ID: 30374835 [TBL] [Abstract][Full Text] [Related]
35. Genome-wide transcriptional profiling analysis reveals annexin A6 as a novel EZH2 target gene involving gastric cellular proliferation. Qi Y; Zhang X; Kang Y; Wu J; Chen J; Li H; Guo Y; Liu B; Shao Z; Zhao X Mol Biosyst; 2015 Jul; 11(7):1980-6. PubMed ID: 25947258 [TBL] [Abstract][Full Text] [Related]
36. Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers. Cohen AL; Piccolo SR; Cheng L; Soldi R; Han B; Johnson WE; Bild AH BMC Med Genomics; 2013 Sep; 6():35. PubMed ID: 24079712 [TBL] [Abstract][Full Text] [Related]
37. EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation. Adamik J; Jin S; Sun Q; Zhang P; Weiss KR; Anderson JL; Silbermann R; Roodman GD; Galson DL Mol Cancer Res; 2017 Apr; 15(4):405-417. PubMed ID: 28119431 [TBL] [Abstract][Full Text] [Related]
38. Epigenetic regulation in human melanoma: past and future. Sarkar D; Leung EY; Baguley BC; Finlay GJ; Askarian-Amiri ME Epigenetics; 2015; 10(2):103-21. PubMed ID: 25587943 [TBL] [Abstract][Full Text] [Related]
39. Aberrant epigenetic regulation in clear cell sarcoma of the kidney featuring distinct DNA hypermethylation and EZH2 overexpression. Karlsson J; Valind A; Jansson C; O'Sullivan MJ; Holmquist Mengelbier L; Gisselsson D Oncotarget; 2016 Mar; 7(10):11127-36. PubMed ID: 26848979 [TBL] [Abstract][Full Text] [Related]
40. Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expression. Kopparapu PK; Bhoi S; Mansouri L; Arabanian LS; Plevova K; Pospisilova S; Wasik AM; Croci GA; Sander B; Paulli M; Rosenquist R; Kanduri M Epigenetics; 2016 May; 11(5):335-43. PubMed ID: 27052808 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]